PBAC's latest decision on Anastrozole, everolimus, exemestane, goserelin, letrozole: Recommended (2014). Considered for Breast cancer in male and female patients. The submission sought to amend PBS restrictions to allow males with breast cancer equitable access to these five hormone therapies, which were previously restricted to post-menopausal women.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Male and female patients with breast cancer (hormone receptor positive); previously the restrictions explicitly limited subsidy to post-menopausal women.
Therapy area
Oncology
Line of therapy
Any
Evidence base
Cost-minimisation
Economic model
Not modelled
ICER note
No economic evaluation submitted; this was a restriction amendment request for equity of access based on gender.